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A B S T R A C T
Ageing increases the risk and severity of infectious diseases, especially when chronic diseases are
present. Healthcare providers generally view vaccination as a childhood intervention and consider
vaccination of the elderly not to be sufﬁciently effective due to immunosenescence. However, the burden
of frequent vaccine-preventable diseases, such as inﬂuenza, pneumococcal disease and herpes zoster,
increases with age, so that the perceived lower vaccine effectiveness should be considered in the context
of this higher burden. Vaccination can prevent infection and mortality hospitalization and functional
decline, and their consequences thereby having a positive impact. The use of medications will be reduced
(e.g. antibiotics, analgesics) and therefore the iatrogenic risk would be lower. This contributes to an
improved quality of life and to successful ageing. Many countries recommend inﬂuenza and
pneumococcal vaccination in the elderly and, more recently, some recommend the live-attenuated
herpes zoster vaccine. However, better guidelines and recommendations, especially for frail individuals
are needed. Protection may be improved by offering vaccination to younger, ﬁtter individuals, before
they become frail. In addition, offering vaccination to caregivers and others who are in contact with the
elderly could also improve protection. Many studies have demonstrated that inﬂuenza, pneumococcal
and herpes zoster vaccinations in the elderly are cost-effective and can even be cost-saving. Healthcare
providers and public health decision-makers need to understand more fully the value of vaccination and
to consider it as an important preventive tool in the promotion of successful ageing.




Ageing is one of the greatest social and economic challenges of
the 21st century. Life expectancy is continuing to increase and
many populations are going through major demographic changes
resulting in a much older population structure. It is estimated that
by 2025, more than 20% of Europeans will be aged  65 years, with
a bigger increase of those aged  80 years. Since ill health and
disability increases with age, ageing populations place a greater
burden on society generally and healthcare systems in particular.Abbreviations: BADL, basic activities of daily living; IADL, instrumental activities of
daily living; CMV, cytomegalovirus; HZ, herpes zoster; VZV, varicella zoster virus;
PHN, post-herpetic neuralgia; ZBPI, Zoster Brief Pain Inventory; PCV, pneumococcal
conjugate vaccine; HCPs, healthcare professionals.
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1878-7649/ 2016 Elsevier Masson SAS and European Union Geriatric Medicine SocieIn this paper, we will examine the role of vaccination in a global
approach to successful, independent ageing and increased healthy-
life expectancy.
2. Higher risk of infectious diseases in the elderly
Ageing does not affect people’s health in the same way, but
about 80% of older people ( 65 years old) have at least one
underlying chronic disease (‘usual ageing’), and 25% have more
than three underlying chronic diseases [1]. While some seniors
‘age successfully’ and have no underlying chronic diseases, others
become frail and can need long-term care in specialised facilities. It
is not easy to predict how people will age, but many factors have
been reported to contribute, such as chronic diseases, functional
status, ageing immune system (immunosenescence), loss of
mechanical barrier function and increased risk of exposure in
congregated settings, including nursing homes [2]. Poor nutritional
status and lack of physical activity can contribute to an increasedty. All rights reserved.
Fig. 1. Older adults have decreased immunity and a higher prevalence of comorbidities that increase their risk of infections. In addition, their performance of basic activities of
daily living prior to infection is a major determinant of survival after infection [3].
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underlying chronic diseases increase the risk of complications
(Fig. 1) [3–5]. Recent research in geroscience is beginning to
provide insights into how fundamental biologic processes of aging,
such as inﬂammation, oxidative stress, tissue senescence including
the immune system, and dysregulation of a variety of homeostatic
mechanisms, could be delayed to extend ‘healthspan’, i.e. the
healthy period of life and delay the development of chronic
diseases and disability [6].
Infectious diseases in seniors often accelerate the decline in
their functional status. This can be measured by the decline in basic
and instrumental activities of daily living (BADL and IADL). BADL
include personal care and hygiene, mobility and being able to get in
and out of bed or up from a chair or sofa, toileting, bathing and
feeding. IADL include cleaning and laundering, cooking and
preparing food, shopping, gardening, driving or using public
transport, managing medications and being able to handle
ﬁnances. Many causes of catastrophic disability, deﬁned as loss
of independence for  3 BADL, are preventable. For example,
pneumonia and inﬂuenza infections, which are ranked 3rd among
these causes can be prevented by vaccination [7–9]. Among those
who experience catastrophic disability, 72% have been hospitali-
sed; 33% of seniors are more disabled at hospital discharge
compared with their pre-illness baseline and half of them will
never recover their previous level of independence [10]. Moreover,
the one-year mortality rate in seniors discharged with new or
additional BADL disabilities was reported to be 41.3%. Failure to
recover was predicted independently by age, cardiovascular
disease, dementia, cancer, low albumin and higher number of
dependencies in IADLs [11]. A clinical prediction rule developed for
assessing the risk of serious inﬂuenza-associated complications
showed that while age was important (i.e. 58 points for those
 90 vs. 0 for those < 70), other factors also contribute, such as
 1 outpatient visit/month (33 points) or previous hospitalisation
for inﬂuenza or pneumonia (63 points) [12]. Vaccination against
seasonal inﬂuenza has also been shown to protect against
pneumonia, complications and even death, and is one means of
preventing hospitalization [13–15]. Therefore, one effective means
of preventing this decline is to prevent infectious diseases.
The frailty proﬁle is partly explained by an imbalance between
inﬂammatory and anti-inﬂammatory processes, which leads to a
low-grade chronic pro-inﬂammatory state termed inﬂammaging
[16]. Inﬂammatory mediators are important in resistance to
infectious diseases during life, but with age they are not efﬁciently
neutralised and are constantly present, leading to inﬂammaging
and unsuccessful ageing. These chronic inﬂammatory processes
increase susceptibility to chronic diseases and infectious diseases.
The production of anti-inﬂammatory mediators in response to thischronic inﬂammation has been associated with more successful
ageing. Current efforts to increase health span centre on slowing
the fundamental biological processes of aging such as inﬂamma-
tion/oxidative stress, increased senescence, mitochondrial dys-
function, impaired proteostasis and reduced stress resistance [6].
Persistent infection with cytomegalovirus (CMV), which belongs
to the herpes family of viruses, is very common. The infection can be
spread by organ transplant, respiratory droplets, saliva, sexual
contact and urine, and most people are infected by mid-life.
Although most people will come into contact with CMV in their
lifetime, healthy people generally do not have symptoms although
the virus remains in a persistent state in multiple sites in the body.
CMV seropositivity has been reported to increase with age and
persistent CMV infection causes CD8+ T cells to become perma-
nently differentiated, with poor proliferative response, the senes-
cent phenotype, which contributes to inﬂammaging [17].
2.1. Vaccine-preventable infectious diseases that contribute to
catastrophic disability in seniors
Many infectious diseases, such as inﬂuenza and pneumonia,
show J-curves for incidence and mortality, with younger and older
individuals having a higher burden of disease and mortality. In
contrast, the curve for immunity is a reverse J-curve, increasing
from a young age up to a peak at about 50 years, and then
declining. The decline is not homogeneous; some seniors retain
good natural immunity and have good responses to vaccination,
while others are more susceptible to infection (as discussed above)
and have lower responses to vaccination. In addition to pneumonia
and inﬂuenza, herpes zoster (HZ), another vaccine-preventable
disease, can contribute to functional decline and loss of autonomy
[18–20]. The higher disease burden and the lower immunity
contribute to the higher risk for catastrophic disability.
Primary infection with varicella zoster virus (VZV) causes
varicella and then the virus remains latent in the sensory ganglia
[21]. HZ is due to reactivation of the latent VZV and, although the
exact mechanism of reactivation is not well known, declining
immunity with age (immunosenescence) has been reported to be
the main risk factor [21]. The complications of HZ can be
neurological, ophthalmic, dermatological and visceral, but the most
important, both in terms of incidence and severity is postherpetic
neuralgia (PHN) [21]. HZ occurs more frequently in older individuals,
with about 2/3rd of cases in those aged  50 years and about 2/3rd of
PHN in those aged  70 years [18,19,22–25].
Even when analgesics and antiviral treatment are initiated soon
after onset, chronic PHN can occur. For example, in a French study
of HZ in general practice (ARIZONA), 80% of the patients received
treatment but 10% had PHN at 1 year [18,26]. A speciﬁc tool, the
Fig. 2. Zoster Brief Pain Inventory (ZBPI) score as a function of age in the placebo
group of a randomised clinical trial assessing herpes zoster vaccine vs. placebo
[20,27].
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the impact of HZ/PHN-related pain and discomfort on seven
general activities: work, sleep, walking, life enjoyment, mood,
relations with others and general activity [20,27,28]. The results in
the placebo group of a zoster vaccine clinical trial showed that the
impact on ADL increased with age, and the impact continues after
resolution of pain [20,29] (Fig. 2).
3. Strategies for improving vaccination effectiveness in the
elderly
Although vaccines are available, there are some concerns about
their protective potential in elders. Declining immune function in
older individuals can reduce their ability to mount an effective
immune response when vaccinated. As was mentioned previously,
immune responsiveness increases from a young age up to peak at
about 50 years, and then declines. One approach being explored
involves modifying immune function to improve immune re-
sponse, but this is only experimental [30]. Another approach is toFig. 3. Multifactorial approach to vaccination in older adults: lifelong vaccination
strategy.modify the vaccine itself or its mode of administration to enhance
the immune response. This approach has been used for inﬂuenza
vaccine, for example, by increasing the vaccine dose, adding an
adjuvant or administering via an intradermal route [31]. Another
strategy would be to vaccinate adults before immunosenescence is
too advanced. This requires knowing the duration of protection in
this population and if boosting is needed, which is not known for
pneumococcal and HZ vaccines at present.
Another problem concerns acceptance of adult vaccination and
its impact on vaccine uptake in elderly populations, which is often
low. Childhood vaccination, unlike vaccination in younger and
older adults, is considered to be a beneﬁcial intervention. Evidence
suggests that prevention of HZ can prevent functional decline and
maintain quality of life in seniors and thus contribute to successful
ageing. This is likely to be true for inﬂuenza and pneumococcal
pneumonia that can be associated with serious complications and
lead to hospitalization. Their effective prevention would prevent
functional decline and improve the health span of older adults
[18,20,27,28,32].
The most efﬁcacious vaccine can only be effective if it is
administered. Since the uptake rates for the elderly are variable
and are often low, we need to identify efﬁcient strategies to
improve vaccine uptake and effectiveness. Vaccination strategies
can be age-based, risk-based or a mix and each has its strengths
and weaknesses.
The risk for infectious diseases increases as immune function
declines, so we need to identify an optimal age when the immune
system can respond effectively to vaccines. However, people with
the same chronological age do not necessarily have the same
biological age and their immune response will vary. Many vaccines
for seniors are recommended for those aged  65 years, when the
immune system is already less reactive in many individuals,
whereas if they were recommended for those aged  50 years old,
more individuals will be able to mount a better immune response
[33]. For example, most countries recommend seasonal inﬂuenza
vaccination for those aged  65 years, but some also recommend
this for healthy individuals aged 50–65, e.g. Belgium [34]. Another
strategy could be lifelong vaccination, with regular boosters, to
keep antibodies above protective levels, as is generally recom-
mended for tetanus and diphtheria. More recently, recommenda-
tions for seasonal inﬂuenza vaccination in the US have been
extended to all individuals aged  6 months [35]. Extending the
recommendations to younger individuals, and particularly to a
lifelong vaccination recommendation, will, naturally, have eco-
nomic repercussions. Starting vaccination earlier in life means that
more people will need to be vaccinated and for longer. However,
these additional costs need to be balanced against vaccination
beneﬁts and risk reductions. Some countries use risk-based
strategies to deﬁne the vaccination target population, but many
elderly people who have underlying comorbidities are unaware
that they have risk factors for infectious diseases. For inﬂuenza and
pneumonia many countries have a mix of age- and risk-based
strategies, so that those who are at risk because of their age (young
children and older adults) are also included in the strategy as well
as those of any age with recognised risk factors.
Another strategy that has been used involves taking advantage
of the indirect or herd protection afforded by some vaccines. For
example, vaccinating children, who generally have better uptake
rates, can provide protection for nontargeted age groups. For
example, in Japan, inﬂuenza vaccination was recommended for
children from 1962 to 1994; this was shown to reduce excess
mortality from pneumonia and inﬂuenza in the elderly; after the
programme was abandoned an increase of excess pneumonia and
inﬂuenza mortality was observed [36]. Other studies in the US have
shown that seasonal inﬂuenza vaccination for children reduced
medically-attended acute respiratory diseases in adults aged
J.E. McElhaney et al. / European Geriatric Medicine 7 (2016) 171–175174 35 years and pneumonia and inﬂuenza hospitalization rates in
those age  65 years, although vaccine uptake was low in the
elderly [37–39]. Similar beneﬁts have been reported in modelling
studies in the UK and Germany [40,41]. This indirect protection
was observed following the introduction of pneumococcal conju-
gate vaccine (PCV) for children in many countries [42,43].
The elderly have frequent health contacts as they often
have underlying diseases. Several observational studies and
randomized clinical trials have shown that seasonal inﬂuenza
vaccination of healthcare professionals in nursing homes and
hospitals can reduce inﬂuenza-like-illness, and inﬂuenza in their
patients [44–49].
4. Conclusions
Preventing infectious diseases and their complications in the
elderly will contribute to maintaining their functional status and
thus healthy ageing. Although efﬁcacious vaccines are available, it
is important to ensure that effective vaccination strategies are
implemented and that vaccine uptake is sufﬁcient. This includes
deﬁning an optimal age for vaccination to ensure that the resulting
immune response is protective, and evaluating the advantages of
lifelong strategies, like those used for tetanus and diphtheria
(Fig. 3). The strategies for inﬂuenza and pneumonia vaccination
could involve taking advantage of indirect protection by vaccinat-
ing children and HCPs who are in contact with their older
grandparents or patients, respectively. It is likely that no one
strategy will be sufﬁcient or suitable for all settings, so a
combination approach will need to be developed and adapted to
individual healthcare settings/systems. Efﬁcacious vaccines are
available to prevent many diseases that affect the elderly,
particularly, inﬂuenza, pneumonia and HZ and they will have an
important role to play to achieve successful aging in our
increasingly ageing populations.
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